According to a new report, published by KBV research, The Global Fibromyalgia Treatment Market size is expected to reach $4 billion by 2030, rising at a market growth of 4.4% CAGR during the forecast period.
The Anticonvulsants segment is leading the Global Fibromyalgia Treatment Market by Drug Class in 2022 thereby, achieving a market value of $2 billion by 2030. This is due to the increased use of anticonvulsant drugs in treating fibromyalgia. Anticonvulsants, such as pregabalin pills, have been licensed to treat fibromyalgia and have earned a lot of support from patients and medical professionals. Anticonvulsants are also a top choice for many patients due to their effectiveness in treating fibromyalgia symptoms, notably in easing pain and enhancing sleep. As a result, there is a greater need for anticonvulsant drugs, fueling the segment's expansion.
The Online Providers segment is showcasing a CAGR of 5.1% during (2023 - 2030). This is due to the ease of ordering fibromyalgia drugs and associated supplies from the comfort of one's home with online retailers. Patients who like the convenience of internet shopping and may have restricted mobility or experience difficulties physically visiting stores are drawn to this accessibility. Additionally, online pharmacies frequently provide affordable prices for fibromyalgia drugs. This accessibility may be a motivating element for patients looking for affordable fibromyalgia treatment choices and increase the use of online providers to get fibromyalgia drugs, which will surge the segment's expansion.
The North America market dominated the Global Fibromyalgia Treatment Market by Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1.5 billion by 2030. The Europe market is exhibiting a CAGR of 4% during (2023 - 2030). Additionally, The Asia Pacific market would showcase a CAGR of 5.2% during (2023 - 2030).
Full Report: https://www.kbvresearch.com/fibromyalgia-treatment-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of AbbVie, Inc., Novartis AG, Eli Lilly And Company, Amneal Pharmaceuticals, Inc., Teva Pharmaceuticals Industries Ltd., Zydus Lifesciences Ltd., Lupin Limited, Abbott Laboratories, Viatris, Inc., and Sun Pharmaceutical Industries Ltd.
By Drug Class
By Distribution Channel
By Geography
Companies Profiled
Unique Offerings 
